En-in-dicycloether is the archive spelling for the chamomile spiroether more commonly written in the literature as en-yn-dicycloether, especially the cis or Z isomer. The strongest evidence for this constituent is analytical and chemotaxonomic rather than clinical: public sources support its identity, its recurring presence in German and Roman chamomile, and modern isolation or quantification work that treats it as a major chamomile marker. Constituent-specific human safety or therapeutic data remain sparse, so AromaForge should frame this record mainly through identity, occurrence, and honestly labeled evidence gaps.
Chemical identity and composition
PubChem CID 103031 resolves the cis or Z form as 2-hexa-2,4-diynylidene-1,6-dioxaspiro[4.4]non-3-ene with formula C13H12O2 and synonyms including en-yn-dicycloether and cis-Tonghaosu. The archive oil file uses the spelling en-in-dicycloether, which appears to be a transliteration or transcription variant of en-yn-dicycloether. In local chamomile oil data, the constituent is listed at 6.22% in the Firoozabad profile, while cited comparison data in that same oil file report broader chamomile ranges around 17-22% in some Estonian samples.
Aroma and practical use
- Use the recorded herbaceous, green, chamomile-like, sweet descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2014 open article on German chamomile cultivated in Firoozabad, Iran reported en-in-dicycloether at 6.22% and listed it among the main oil constituents.
A 2014 open article on German chamomile cultivated in Firoozabad, Iran reported en-in-dicycloether at 6.22% and listed it among the main oil constituents.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2007 quantitative study established an HPLC-PAD-MS method for cis-en-yn-dicycloether and trans-en-yn-dicycloether and reported that flowers of the two tested chamomile species contained large amounts of both isomers, with trans-form levels exceeding cis-form levels in those samples.
A 2007 quantitative study established an HPLC-PAD-MS method for cis-en-yn-dicycloether and trans-en-yn-dicycloether and reported that flowers of the two tested chamomile species contained large amounts of both isomers, with trans-form levels exceeding cis-form levels in those samples.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2021 open-access isolation paper reported that (Z)-en-yn-dicycloether co-eluted with alpha-bisabolol oxide A and required additional size-exclusion chromatography for clean separation, reinforcing its real analytical importance in chamomile matrices.
A 2021 open-access isolation paper reported that (Z)-en-yn-dicycloether co-eluted with alpha-bisabolol oxide A and required additional size-exclusion chromatography for clean separation, reinforcing its real analytical importance in chamomile matrices.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No clean public CAS number or constituent-specific IFRA-style restriction for isolated en-yn-dicycloether was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because the located literature is dominated by chamomile composition and isolation work, archive copy should avoid implying established standalone therapeutic or toxicological conclusions for this molecule.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
no human validated constituent mechanism verified
No well-validated human physiological mechanism for isolated en-yn-dicycloether was confirmed in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
analytical marker behavior in chamomile
The most direct support for this constituent is analytical: modern isolation and quantification studies repeatedly use cis/trans spiroether behavior to characterize chamomile extracts and flower materials.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- A clean public CAS record for the archive spelling en-in-dicycloether was not verified.
- Human clinical, dermal, inhalation, reproductive, and chronic toxicology data for isolated en-yn-dicycloether were not verified in this pass.
- Some sources distinguish cis/Z and trans/E spiroether isomers explicitly, while the archive constituent id does not.
- dermal_limit_pct corrected from an unsourced 0.1 to null (2026-07-13): no IFRA/RIFM numeric leave-on limit for isolated en-in-/en-yn-dicycloether was located. An FDA science-forum case study on skin sensitization potential of German chamomile using integrated testing approaches evaluated umbelliferone, apigenin, kaempferol, isorhamnetin, nerol, alpha-terpinene, carvone (positive) and caffeic acid, t-ferulic acid, cosmosiin, hyperoside, alpha-terpineol, alpha-bisabolol, chamazulene (negative) for sensitization, but did not include the spiroether/dicycloether compounds in that tested set, so sensitizing remains null (genuinely unknown) rather than assumed negative.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.